| Business Summary | | Celera
Genomics
Group,
a
business
of
Applera
Corporation,
is
engaged
principally
in
the
generation,
sale
and
support
of
genomic
information
and
enabling
data
management
and
analysis
software.
The
Celera
Genomics
Group's
customers
use
this
information
for
commercial
applications
in
the
pharmaceutical
and
life
sciences
industries
in
the
specific
areas
of
target
identification,
drug
discovery
and
drug
development.
The
Celera
Genomics
Group
also
provides
gene
discovery,
genotyping
and
related
genomics
services.
The
Celera
Genomics
Group
has
recently
expanded
its
business
into
the
emerging
fields
of
functional
genomics,
particularly
proteomics
and
personalized
health/medicine. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CRA,
a
business
of
Applera
Corp.,
engages
in
the
generation,
sale
and
support
of
genomic
information
and
related
software;
discovery,
licensing
and
validation
of
proprietary
gene
products;
genetic
markers,
genetic
variablity,
and
related
consulting
and
R&D
services.
For
the
nine
months
ended
3/31/01,
sales
totaled
$61.9
million,
up
from
$27.7
million.
Net
loss
rose
25%
to
$84.5
million.
Results
reflect
higher
subscription
agreements,
offset
by
amortization
of
goodwill. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
27,400;
after
tax
earnings
were
-101,700. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| J. Venter, 52 Pres
of Clera Genomics and Sr. VP of PE Corp. | $2.1M | Jason Molle Sr.
VP of Sales and Marketing | -- | Peter Barrett, 46 VP | -- | Samuel Broder, 54 VP | -- | James Peck, 36 VP,
Product Devel. | -- | Dollar amounts are as of 30-June-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|